Platelet-activation and Optimal Inhibition in Patients With Atrial Fibrillation Undergoing Left Atrial Appendage Occlusion

Atrial Fibrillation Clinical Trial

— POPULAR-LAAO  

Official title:

Platelet-activation and Optimal Inhibition in Patients With Atrial Fibrillation Undergoing Left Atrial Appendage Occlusion; The POPULAR-LAAO Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04705688
• Other study ID #: RDC-2020.02
• Status: Recruiting
• Start date: February 24, 2021
• Est. completion date: December 2024

Study information

• Verified date: March 2021
• Source: R&D Cardiologie
• Contact: Lucas VA Boersma, MD PhD
• Phone: +31 088 320 3000
• Email: l.boersma[@]antoniusziekenhuis.nl
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The POPULAR-LAAO registry is an open-label observational prospective registry to investigate hemostatic processes following left atrial appendage occlusion.

Description:

This is an open-label observational prospective registry. The aim is to develop a better understanding of coagulation, platelet reactivity and prothrombotic factors in the first months after left atrial appendage occlusion, as occurrence of device-related thrombus and optimal postprocedural management remain a challenge after LAAO.

The study population will consist of patients with non-valvular atrial fibrillation (AF) at risk for cardio-embolic stroke scheduled for left atrial appendage occlusion. In these patients, blood samples for coagulation and platelet reactivity testing will be taken, which will be gathered prior to the procedure and 1 day, 14 days, 3 months and 6 months after the procedure. Data will be analyzed longitudinally and between groups based on patient characteristics.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 120
• Est. completion date: December 2024
• Est. primary completion date: December 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• The subject is aged 18 years or older

• The subject is accepted/scheduled for left atrial appendage occlusion

• The subject has a CHA2DS2-VASc Score =2 (male) or =3 (female)

• The subject or legal representative is able to understand and is willing to provide written informed consent to participate in the trial.

Exclusion Criteria:

• Unable or unwilling to return for required follow-up visits and examinations

• Mechanical heart valves or valvular disease requiring surgery or interventional procedure

• Ongoing major bleeding or complicated or recent (<72hours) major surgery

• Known large oesophageal varices or decompensated liver disease (unless a documented positive opinion of a gastro-enterologist)

• Severe thrombocytopenia (<50,000/ml)

• High likelihood of being unavailable for follow-up or psycho-social condition making study participation impractical.

• Woman with child bearing potential who do not use an efficient method of contraception.

• Positive serum or urine pregnancy test for woman with child bearing potential

• Pregnancy or within 48 hours post-partum

• unsuitable LAA anatomy for occlusion or thrombus in the LAA at the time of procedure

• contraindications or unfavourable conditions to perform cardiac catheterization or transesophageal echocardiography (TEE)

• atrial septal malformations, atrial septal defect or a high-risk patent foramen ovale that may cause thrombo-embolic events

• atrial septal defect repair or closure device or a patent foramen ovale repair or any other anatomical condition as this may preclude an LAAO procedure

• Mitral valve regurgitation grade 3 or more

• Aortic valve stenosis (AVA<1.0 cm2 or Pmax>50 mmHg) or regurgitation grade 3 or more

• Planned carotid endarterectomy (CEA) for significant carotid artery disease

• Life expectancy of less than 1 year

Related Conditions & MeSH terms

• Atrial Fibrillation

Locations

Country	Name	City	State
Netherlands	St. Antonius Ziekenhuis	Nieuwegein	Utrecht

Sponsors (1)

Lead Sponsor	Collaborator
R&D Cardiologie

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in coagulation activation	Influence of LAAO on coagulation activation over time	Pre-LAAO and post-LAAO (1 day, 2 weeks, 3 months, 6 months)
Primary	Change in platelet reactivity	Influence of LAAO on platelet reactivity over time	Pre-LAAO and post-LAAO (1 day, 2 weeks, 3 months, 6 months)
Primary	CYP2C19 genotype	Rate of clopidogrel non-responders among LAAO patients will be assessed by determining CYP2C19 genotype	Pre-LAAO
Secondary	Separate and composite event rates of stroke (ischemic or hemorrhagic), transient ischemic attack (TIA), systemic embolism and cardiovascular death.		Post-LAAO (3 months, 6 months, 12 months)
Secondary	Major and minor bleeding event rate (according to Bleeding Academic Research Consortium criteria)		Post-LAAO (3 months, 6 months, 12 months)
Secondary	Device related thrombus event rate		Post-LAAO (3 months, 12 months)